linjc16/ctgov huggingface dataset:
Effects of Interscalene Brachial Plexus Nerve Blocks on the Hand and Forearm

Study Overview
=================
Brief Summary
-----------------
Research study to determine the proportion of cases in which an interscalene brachial plexus nerve block produces hand and forearm anesthesia.

Detailed Description
-----------------
This is a research study to prospectively determine the proportion of cases in which an interscalene brachial plexus nerve block produces hand and forearm anesthesia. The investigators will investigate this issue in patients having shoulder and not hand/forearm surgery. We will test hand grip strength and sensation to determine if the hand and forearm are responding to the anesthesia.

Official Title
-----------------
Effects of Interscalene Brachial Plexus Nerve Blocks on the Hand and Forearm

Conditions
-----------------
Shoulder Surgery, Interscalene Nerve Block

Intervention / Treatment
-----------------
* Procedure: Interscalene Nerve Block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older unilateral orthopedic shoulder surgery already desiring an interscalene brachial plexus nerve block for postoperative analgesia with the anesthetic plan including a preoperative interscalene nerve block with mepivacaine Exclusion Criteria: any known contraindication to study medications or testing hand grip strength pre/post-op insulin-dependent diabetes mellitus neuropathy of any etiology in the affected extremity any anticipated incision site apart from the shoulder Obesity Pregnancy Incarceration inability to communicate with the investigators and hospital staff

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Shoulder Surgery<br>Patients will be given an interscalene nerve block and then strength and sensation of the hand and forearm will be tested to determine if the block is helping to anesthetize these areas. | Procedure: Interscalene Nerve Block<br>* Patients undergoing shoulder surgery will be given an Interscalene Nerve Block. The patients' strength and sensation in their hand and forearm will be tested to determine if the nerve block is affectively delivering anesthetic to the nerves that serve these areas.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
UCSD, Perineural Nerve Block, Shoulder Surgery, Pain, Grip Strength, Sensation, Interscalene Nerve Block
Molecular Diagnosis of Syndromic or Isolated Severe Intellectual Disability Using Whole Exome Sequencing : a Pilot Study

Study Overview
=================
Brief Summary
-----------------
Evaluation of diagnostic whole exome sequencing in patients with syndromic or isolated severe intellectual disability without a molecular diagnostic, with suspected autosomal recessive inheritance, allowing accurate genetic counseling in this high risk of recurrence group of diseases

Official Title
-----------------
Molecular Diagnosis of Syndromic or Isolated Severe Intellectual Disability Using Whole Exome Sequencing : a Pilot Study

Conditions
-----------------
Severe Intellectual Disability

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of syndromic or isolated severe intellectual disability (IQ <50) without a molecular diagnosis Recurrence in siblings (multiplex families) suggesting autosomal recessive inheritance (with or without parental consanguinity) or sporadic cases from a consanguineous union Conventional genetic tests performed (including array-CGH) and MRI/CT-scan available DNA samples from parents and from both unaffected or affected siblings available, for parental segregation and confirmation of candidate variations identified. Availability of a signed informed consent To be affiliated or beneficiary of French social security/healthcare system Exclusion Criteria: Parents in the exclusion period of another study or as provided by the national register of volunteers High-probability diagnostic hypothesis for which a molecular test is available at lower cost than exome sequencing
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with a molecular diagnostic and diagnostic yield |  | up to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cost/diagnostic ratio in comparison with conventional techniques |  | up to 12 months | 
| Reporting time in comparison with conventional techniques |  | up to 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Whole exome sequencing, Molecular diagnostic, Genetic counselling
Association of Coronary Artery Disease With Lewis and ABO Blood Group Phenotypes

Study Overview
=================
Brief Summary
-----------------
Primary objective- To study the association of Lewis antigen and A, B, O blood group phenotypes with coronary artery disease patients attending the tertiary care hospital in Kerala. The secondary objective-To find the association of Lewis antigen and A, B, O blood group phenotypes with smoking, alcohol use, diabetes, hypertension and dyslipidemia. A case-control study to compare the prevalence of Lewis(a-b-) blood group among confirmed cardiac cases with the prevalence of the same among the general population and thereby find out if individuals with Lewis(a-b-) are more at risk of developing coronary artery disease. This may provide an economical and simple method for identifying subjects at increased risk for coronary artery disease and subsequently lead to more focused preventive measures and eventually to a specific treatment.

Official Title
-----------------
Association of Coronary Artery Disease With Lewis and ABO Blood Group Phenotypes- A Case Control Study

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients in the age group of 30-55 years at the time of data collection diagnosed with coronary artery disease based on positive changes in coronary angiogram (more than 70% coronary stenosis) Exclusion Criteria: Patients with other systemic illnesses like malignancy, autoimmune diseases. Patients who were not willing to participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CASE(coronary artery disease)<br>Patients with confirmed coronary artery disease | |
| CONTROL<br>People without coronary artery disease | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of Lewis and ABO blood group phenotypes in cases and controls. | Prevalence Lewis and ABO phenotype in cases will be compared to prevalence of the same in controls. | Lewis and ABO phenotype of the study participants was determined immediately after sample collection | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ABO blood group system, Lewis negative phenotype, coronary artery disease
Remote Collection of Patient Reported Toxicity Using SMS Text Messaging (CareSignal)

Study Overview
=================
Brief Summary
-----------------
CareSignal has developed an application that allows for remote collection of patient-reported data such as symptoms or outcomes on any device compatible with the short message service (SMS), otherwise known as text messaging. The software can be configured to complete symptom monitoring by surveying patients about toxicity using the PRO-CTCAE tools. PRO-CTCAE is the patient reported outcomes version of the CTCAE that was designed by the National Cancer Institute (NCI) for use in clinical trials.

Official Title
-----------------
Remote Collection of Patient Reported Toxicity Using SMS Text Messaging

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Other: CareSignal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Currently planning to receive radiotherapy for 2 or more fractions with or without chemotherapy. Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable). Age 18 years or older. Exclusion Criteria: -Unable to reliably access and use a device compatible with CareSignal software.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CareSignal<br>-Participants will undergo a single training session on how to use the CareSignal software no more than 4 weeks before starting standard of care therapy. After the training session, patients will be encouraged by the treatment team to complete the baseline symptom report once they receive the questions via SMS prior to starting any therapy and to complete the weekly reports during therapy and in follow up. | Other: CareSignal<br>* The CareSignal software will be programmed to automatically ask a subset of the NCI-PRO-CTCAE questions using SMS depending on patient group as designated by the treating physician: (1) thoracic radiation with chemotherapy, (2) thoracic radiation alone, (3) extremity/body wall sarcoma, and (4) other.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of invited symptom reports completed during the study period |  | From treatment through 30 days follow-up (estimated to be 3 months) | 
| Percentage of questions completed within each invited symptom report |  | From treatment through 30 days follow-up (estimated to be 3 months) |
Intralesional Vitamin D Injection for Treatment of Common Warts

Study Overview
=================
Brief Summary
-----------------
Researchers are trying to find out if injecting Vitamin D into a wart is an effective treatment.

Official Title
-----------------
Efficacy of Intralesional Vitamin D Injection for Treatment of Common Warts: A Randomized Controlled Trial

Conditions
-----------------
Warts

Intervention / Treatment
-----------------
* Drug: Vitamin D3
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients seen at the Mayo Clinic Rochester practices Patients suffering from one or more cutaneous warts as diagnosed by the examining physician at baseline visit on typical diagnostic characteristics Able to provide consent Both recalcitrant and non-recalcitrant warts will be included Exclusion Criteria: Patients with prior use of home or office-based destructive treatments for this wart(s) in the last 1 month with SA or cryotherapy Immunoadjuvant therapy for warts in the last 4 months (e.g Candida) History of vitamin D injection of warts ever High-dose vitamin D supplementation (>4,000 IU daily or equivalent) in the preceding 3 months Pregnancy or lactation Facial or genital warts Lesions not felt by the examining clinician to be a wart (e.g., corns or calluses) Immunosuppression (to include immunosuppressive medications or conditions as judged by the physician evaluating the patient at the baseline visit).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vitamin D3 Treatment Group<br>Subjects will receive a Vitamin D3 injection into their wart | Drug: Vitamin D3<br>* Intralesional injection of 0.3 ml 40,000 IU/ml vitamin D3 into one wart<br>* Other names: Cholecalciferol;|
| Placebo Comparator: Placebo Group<br>Subjects will receive a placebo injection into their wart | Drug: Placebo<br>* 0.3 ml injection of sterilized propylene glycol: dehydrated alcohol (9:1 ratio) with no active study ingredient<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete regression of wart | Number of subjects to have a complete resolution of cutaneous wart | Approximately 5 months |
To Compare the Efficacy and Safety of a Therapy of Tacrolimus With Sirolimus or MMF in Kidney Transplantation.

Study Overview
=================
Brief Summary
-----------------
Primary objective of this study is to compare the two therapy regimens with regard to renal function by using calculated creatinine clearance. The secondary objectives are to compare the efficacy and safety profiles of the two therapy regimens.

Detailed Description
-----------------
This phase III study shall provide detailed efficacy and safety information to compare this combination of sirolimus and tacrolimus with the current standard tacrolimus combination regimen (tacrolimus/MMF/steroids) which is widely used in European centres.

Official Title
-----------------
A Multicentre, Randomised, Open Clinical Study to Compare the Efficacy and Safety of a Combination Therapy of Tacrolimus With Sirolimus Versus Tacrolimus With Mycophenolate Mofetil in Kidney Transplantation.

Conditions
-----------------
Kidney Transplantation

Intervention / Treatment
-----------------
* Drug: Tacrolimus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients between 18 and 60 years of age and having end stage kidney disease who will undergo primary renal transplantation or retransplantation are eligible for the study. Patients receiving a kidney transplant, from a cadaveric or living donor (not HLA identical) with compatible AB0 blood type can be included. Exclusion Criteria: Patient has a high immunological risk Cold ischemia time greater than 30 hours Patient has significant liver disease Patient has severe hypercholesterolaemia Patient is allergic or intolerant to study medication Patient requires ongoing dosing with corticosteroids. Patient or donor is known to be HIV positive Patient with malignancy or history of malignancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br> | Drug: Tacrolimus<br>* immunosuppression<br>* Other names: Prograf, FK506;|
| Experimental: 2<br> | Drug: Tacrolimus<br>* immunosuppression<br>* Other names: Prograf, FK506;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Renal function as assessed by calculated creatinine clearance at month 6. |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute rejection: Incidence of and time to first acute rejection |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tacrolimus, Kidney Transplantation, Immunosuppression, Adult, Treatment Outcomes
Oxycodone Concentration in the Blood After Oral Premedication

Study Overview
=================
Brief Summary
-----------------
Oxycodone is an opioid frequently given orally as a premedication prior to any kind of surgery. The initial studies are performed on healthy testpersons and is not given in surgery. The investigators want to explore serum concentration over time (5h) and relate this to Visual Analoge Scale (VAS) postoperatively but also to given mg/kg

Detailed Description
-----------------
Oxycodone is an opioid frequently given orally as a premedication prior to any kind of surgery. The initial studies are performed on healthy test-persons and is not given in surgery. The investigators want to explore serum concentration over time (5h) and relate this to Visual Analoge Scale (VAS) postoperatively but also to given mg/kg 20 female patients between 30 and 60 years will be included after informed consent. They will have day-surgery. The patients will receive 5 mg oxycodone if weighing less than 60 kg and 10 mg if weighing over 60 kg. Serum samples will be taken 1, 2,3,4, and 5 hours after medication intake and serum concentrations will be analyzed

Official Title
-----------------
Oxycodone Concentration in the Blood After Oral Premedication

Conditions
-----------------
Oxycontin

Intervention / Treatment
-----------------
* Drug: Oxycodone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Females <100kg, non-opioid tolerant, day surgery and informed consent Exclusion Criteria: In complying to inclusion criterias

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| day surgery patients<br>20 patients female 30-60 years of age | Drug: Oxycodone<br>* Serum concentration per hour from 1 to 5 h<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oxycodone concentration in the blood after oral premedication | Concentration study | 2 days | 
| Oxycodone concentrations and pain after oral premedication | Visual analoge Scale | 7 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
concentration
Brain Electrophysiological Patterns in Obesity

Study Overview
=================
Brief Summary
-----------------
There is growing evidence of behavioural and neurobiological overlaps between obesity and drug abuse. Reduction of the amplitude of P300, a component of event-related potentials (ERP) elicited by an oddball paradigm, is an electrophysiological characteristic and a marker of vulnerability in substance abuse. We want to determine whether obesity is associated with such electrophysiological features during an auditory oddball paradigm. We postulate that obesity could be associated with electrophysiological abnormalities that could be viewed as a possible vulnerability marker for food addiction.

Official Title
-----------------
ERP Study of Brain Electrophysiological Patterns in Obesity

Conditions
-----------------
Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The inclusion criteria for the study are men and women aged 20-60 years, BMI 18.5-24.9 kg/m2 for control subjects and BMI>30 kg/m2 for obese subjects, stable body weight over the previous 3 months, report of sedentary or moderate physical activity Exclusion Criteria: The exclusion criteria are pregnancy, post-menopausal women, any physiological or psychological illness that could influence the results, subjects likely to take medical drugs interfering with the electrophysiological parameters of the study, diabetes, hearing disorder, intense physical activity and report or evidence of excessive alcohol consumption, depressive state or eating disorders according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal weighted<br>BMI<25 | |
| Obese<br>BMI>30 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of amplitudes and latencies of the P300 complex of Event Related Potential during an oddball paradigm, in normal-weighted and obese subjects |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
obesity, cognitive process, reward, P300, ERP, Event-related potential during oddball paradigm, brain electrophysiological patterns, externalizing factor